Indication-specific pricing may begin to reshape US reimbursement for anti-inflammatory drugs in the first half of 2017, when pharmacy benefit manager Express Scripts Holding Co. launches its new approach to contracting.
In a move away from paying for anti-inflammatory drugs as a broad category, Express Scripts will negotiate separate pricing for the crowded class within four smaller indications: 1) rheumatoid arthritis; 2) psoriasis/psoriatic arthritis; 3) ankylosing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?